<DOC>
	<DOCNO>NCT00790192</DOCNO>
	<brief_summary>Lurasidone HCl compound develop treatment schizophrenia . This clinical study design test hypothesis lurasidone effective , tolerable , safe compare quetiapine XR short term among acutely psychotic patient chronic schizophrenia .</brief_summary>
	<brief_title>Lurasidone HCL - A 6-week Phase 3 Study Patients With Acute Schizophrenia .</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Provide write informed consent age 18 75 year age . Meets DSMIVâ„¢ criterion primary diagnosis schizophrenia . Not pregnant , reproductive potential agrees remain abstinent use adequate reliable contraception duration study . Able agrees remain prior antipsychotic medication duration study . Good physical health basis medical history , physical examination , laboratory screening . Willing able comply protocol , include inpatient requirement outpatient visit . Considered investigator imminent risk suicide injury self , others , property . Any chronic organic disease CNS ( schizophrenia ) . Used investigational compound within 30 day . Clinically significant history alcohol abuse/alcoholism drug abuse/dependence within last 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>SM-13496</keyword>
	<keyword>Latuda</keyword>
	<keyword>Lurasidone</keyword>
</DOC>